Literature DB >> 20675237

Understanding neonatal jaundice: a perspective on causation.

Ronald S Cohen1, Ronald J Wong, David K Stevenson.   

Abstract

Neonatal jaundice can be best understood as a balance between the production and elimination of bilirubin, with a multitude of factors and conditions affecting each of these processes. When an imbalance results because of an increase in circulating bilirubin (or the bilirubin load) to significantly high levels (severe hyperbilirubinemia), it may cause permanent neurologic sequelae (kernicterus). In most infants, an increase in bilirubin production (e.g., due to hemolysis) is the primary cause of severe hyperbilirubinemia, and thus reducing bilirubin production is a rational approach for its management. The situation can become critical in infants with an associated impaired bilirubin elimination mechanism as a result of a genetic deficiency and/or polymorphism. Combining information about bilirubin production and genetic information about bilirubin elimination with the tracking of bilirubin levels means that a relative assessment of jaundice risk might be feasible. Information on the level of bilirubin production and its rate of elimination may help to guide the clinical management of neonatal jaundice. 2010 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675237     DOI: 10.1016/S1875-9572(10)60027-7

Source DB:  PubMed          Journal:  Pediatr Neonatol        ISSN: 1875-9572            Impact factor:   2.083


  12 in total

1.  Effect of metoclopramide administration to mothers on neonatal bilirubin and maternal prolactin: a randomized, controlled, clinical trial.

Authors:  Shirin Osouli Tabrizi; Mojgan Mirghafourvand; Abdollah Jannat Dost; Sakineh Mohammad-Alizadeh-Charandabi; Yousef Javadzadeh; Robabe Seyedi
Journal:  World J Pediatr       Date:  2018-12-05       Impact factor: 2.764

2.  Causes of hemolysis in neonates with extreme hyperbilirubinemia.

Authors:  R D Christensen; R H Nussenzveig; H M Yaish; E Henry; L D Eggert; A M Agarwal
Journal:  J Perinatol       Date:  2014-04-24       Impact factor: 2.521

3.  Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal Hyperbilirubinemia.

Authors:  Andreia Barateiro; Shujuan Chen; Mei-Fei Yueh; Adelaide Fernandes; Helena Sofia Domingues; João Relvas; Olivier Barbier; Nghia Nguyen; Robert H Tukey; Dora Brites
Journal:  Mol Pharmacol       Date:  2015-10-19       Impact factor: 4.436

4.  Rat cerebellar slice cultures exposed to bilirubin evidence reactive gliosis, excitotoxicity and impaired myelinogenesis that is prevented by AMPA and TNF-α inhibitors.

Authors:  Andreia Barateiro; Helena Sofia Domingues; Adelaide Fernandes; João Bettencourt Relvas; Dora Brites
Journal:  Mol Neurobiol       Date:  2013-08-28       Impact factor: 5.590

5.  Time-dependent dual effects of high levels of unconjugated bilirubin on the human blood-brain barrier lining.

Authors:  Inês Palmela; Hiroyuki Sasaki; Filipa L Cardoso; Miguel Moutinho; Kwang S Kim; Dora Brites; Maria A Brito
Journal:  Front Cell Neurosci       Date:  2012-05-10       Impact factor: 5.505

6.  Metalloporphyrins - an update.

Authors:  Stephanie Schulz; Ronald J Wong; Hendrik J Vreman; David K Stevenson
Journal:  Front Pharmacol       Date:  2012-04-26       Impact factor: 5.810

7.  Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study.

Authors:  Inês Palmela; Leonor Correia; Rui F M Silva; Hiroyuki Sasaki; Kwang S Kim; Dora Brites; Maria A Brito
Journal:  Front Neurosci       Date:  2015-03-13       Impact factor: 4.677

8.  Urinary N-acetyl-beta-D-glucosaminidase as an early marker for acute kidney injury in full-term newborns with neonatal hyperbilirubinemia.

Authors:  Bangning Cheng; Yulian Jin; Guanghui Liu; Zhiheng Chen; Hongmei Dai; Min Liu
Journal:  Dis Markers       Date:  2014-06-24       Impact factor: 3.434

9.  Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States.

Authors:  Tzy-Chyi Yu; Chi Nguyen; Nancy Ruiz; Siting Zhou; Xian Zhang; Elaine A Böing; Hiangkiat Tan
Journal:  BMC Pediatr       Date:  2019-02-11       Impact factor: 2.125

10.  Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.

Authors:  Katherine Hu; Zhaowen Zhu; Meleah M Mathahs; Huy Tran; Jerry Bommer; Charles A Testa; Warren N Schmidt
Journal:  Drug Des Devel Ther       Date:  2020-02-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.